Statistical significance: Difference between revisions
imported>Robert Badgett (→Likelihood or Bayesian method: Added formulas) |
imported>Robert Badgett |
||
| Line 27: | Line 27: | ||
The Bayesian method has been proposed for adaptive trial designs for comparative effectiveness research.<ref name="pmid19567619">{{cite journal |author=Luce BR, Kramer JM, Goodman SN, ''et al.'' |title=Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change |journal=Ann. Intern. Med. |volume=151 |issue=3 |pages= |year=2009 |month=June |pmid=19567619 |doi= |url=http://www.annals.org/cgi/content/full/0000605-200908040-00126v1 |issn=}}</ref> In the United States, [[Medicare]]'s [[Centers for Medicare and Medicaid Services]] (CMS) is investigating this role.<ref name="urlHealth Care: Technology Assessment Subdirectory Page">{{cite web |url=http://www.ahrq.gov/clinic/techix.htm#progress |title=Health Care: Technology Assessment Subdirectory Page |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=Agency for Healthcare Research and Quality |pages= |language=English |archiveurl= |archivedate= |quote= |accessdate=2009-08-03}}</ref> | The Bayesian method has been proposed for adaptive trial designs for comparative effectiveness research.<ref name="pmid19567619">{{cite journal |author=Luce BR, Kramer JM, Goodman SN, ''et al.'' |title=Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change |journal=Ann. Intern. Med. |volume=151 |issue=3 |pages= |year=2009 |month=June |pmid=19567619 |doi= |url=http://www.annals.org/cgi/content/full/0000605-200908040-00126v1 |issn=}}</ref> In the United States, [[Medicare]]'s [[Centers for Medicare and Medicaid Services]] (CMS) is investigating this role.<ref name="urlHealth Care: Technology Assessment Subdirectory Page">{{cite web |url=http://www.ahrq.gov/clinic/techix.htm#progress |title=Health Care: Technology Assessment Subdirectory Page |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=Agency for Healthcare Research and Quality |pages= |language=English |archiveurl= |archivedate= |quote= |accessdate=2009-08-03}}</ref> | ||
: | Bayesian inference:<ref name="pmid10383350">{{cite journal |author=Goodman SN |title=Toward evidence-based medical statistics. 2: The Bayes factor |journal=Ann Intern Med |volume=130 |pages=1005–13 |year=1999 |pmid=10383350 |doi=|url=http://www.annals.org/cgi/content/full/130/12/1005}}</ref> | ||
:<math>\text{Prior Odds of Null Hypothesis}\ *\ \text{Bayes Factor}\ =\ \text{Posterior Odds of Null Hypothesis}</math> | |||
The equation for the Bayes Factor is:<ref name="pmid10383350">{{cite journal |author=Goodman SN |title=Toward evidence-based medical statistics. 2: The Bayes factor |journal=Ann Intern Med |volume=130 |pages=1005–13 |year=1999 |pmid=10383350 |doi=|url=http://www.annals.org/cgi/content/full/130/12/1005}}</ref> | |||
:<math>\text{Bayes Factor}\ =\ \frac{\text{Probability of the null hypothesis given the data found}}{\text{Probability of the null hypothesis given the data found}}</math> | |||
{| class="wikitable" align="right" | {| class="wikitable" align="right" | ||
Revision as of 21:36, 3 August 2009
In statistics, statistical significance is a "term indicating that the results obtained in an analysis of study data are unlikely to have occurred by chance, and the null hypothesis is rejected. When statistically significant, the probability of the observed results, given the null hypothesis, falls below a specified level of probability (most often P < 0.05)."[2] The P-value, which is used to represent the likelihood the observed results are due to chance, is defined at "the probability, under the assumption of no effect or no difference (the null hypothesis), of obtaining a result equal to or more extreme than what was actually observed."[3]
Hypothesis testing
Usually, the null hypothesis is the there is no difference between two samples in regard to the factor being studied.[4]
Statistical errors
Two errors can occur in assessing the probability that the null hypothesis is true:
Type I error (alpha error)
Type I error, also called alpha error, is the the rejection of a correct null hypothesis. The probability of this is usually expressed by the p-value. Usually the null hypothesis is rejected if the p-value, or the chance of a type I error, is less than 5%. However, this threshold may be adjusted when multiple hypotheses are tested.[5]
Type II error (beta error)
Type II error, also called beta error, is the acceptance of an incorrect null hypothesis. This error may occur when the sample size was insufficient to have power to detect a statistically significant difference.[6][7][8]
Philosophical approaches to error testing
Frequentist method
This approach uses mathematical formulas to calculate deductive probabilities (p-value) of an experimental result.[3] This approach can generate confidence intervals.
A problem with the frequentist analyses of p-values is that they may overstate "statistical significance".[3][9]
Likelihood or Bayesian method
Some argue that the P-value should be interpreted in light of how plausible is the hypothesis based on the totality of prior research and physiologic knowledge.[10][3][9][11][12] This approach can generate Bayesian 95% credibility intervals.[13]
The Bayesian method has been proposed for adaptive trial designs for comparative effectiveness research.[14] In the United States, Medicare's Centers for Medicare and Medicaid Services (CMS) is investigating this role.[15]
Bayesian inference:[9]
The equation for the Bayes Factor is:[9]
| Bayes Factor (B) |
Interpretation of support for the alternative hypothesis |
|---|---|
| > 1.00 | reduces the odds of the null hypothesis |
| 0.32–1.00 | "not worth more than a bare mention" |
| 0.100–0.320 | "substantial support" |
| 0.032–0.100 | "strong support" |
| 0.010–0.032 | "very strong support" |
| < 0.010 | "decisive support" |
References
- ↑ Anonymous (2006). “Normal Distribution”, NIST/SEMATECH e-Handbook of Statistical Methods. Gaithersburg, MD: National Institute of Standards and Technology. Retrieved on 2009-02-10.
- ↑ Anonymous. JAMAevidence Glossary. American Medical Association. Retrieved on 2009-02-10.
- ↑ 3.0 3.1 3.2 3.3 Goodman SN (1999). "Toward evidence-based medical statistics. 1: The P value fallacy". Ann Intern Med 130: 995–1004. PMID 10383371. [e]
Cite error: Invalid
<ref>tag; name "pmid10383371" defined multiple times with different content - ↑ Mosteller, Frederick; Bailar, John Christian (1992). Medical uses of statistics. Boston, Mass: NEJM Books. ISBN 0-910133-36-0. Google Books
- ↑ Hochberg, Yosef (1988-12-01). "A sharper Bonferroni procedure for multiple tests of significance". Biometrika 75 (4): 800-802. DOI:10.1093/biomet/75.4.800. Retrieved on 2008-10-15. Research Blogging.
- ↑ Altman DG, Bland JM (August 1995). "Absence of evidence is not evidence of absence". BMJ (Clinical research ed.) 311 (7003): 485. PMID 7647644. PMC 2550545. [e]
- ↑ Detsky AS, Sackett DL (April 1985). "When was a "negative" clinical trial big enough? How many patients you needed depends on what you found". Archives of internal medicine 145 (4): 709–12. PMID 3985731. [e]
- ↑ Young MJ, Bresnitz EA, Strom BL (August 1983). "Sample size nomograms for interpreting negative clinical studies". Annals of internal medicine 99 (2): 248–51. PMID 6881780. [e]
- ↑ 9.0 9.1 9.2 9.3 Goodman SN (1999). "Toward evidence-based medical statistics. 2: The Bayes factor.". Ann Intern Med 130 (12): 1005–13. PMID 10383350.
Cite error: Invalid
<ref>tag; name "pmid10383350" defined multiple times with different content Cite error: Invalid<ref>tag; name "pmid10383350" defined multiple times with different content Cite error: Invalid<ref>tag; name "pmid10383350" defined multiple times with different content - ↑ Browner WS, Newman TB (1987). "Are all significant P values created equal? The analogy between diagnostic tests and clinical research". JAMA 257: 2459–63. PMID 3573245. [e]
- ↑ Diamond GA, Kaul S (June 2004). "Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials". J. Am. Coll. Cardiol. 43 (11): 1929–39. DOI:10.1016/j.jacc.2004.01.035. PMID 15172393. Research Blogging.
- ↑ Ioannidis JP (August 2008). "Effect of formal statistical significance on the credibility of observational associations". Am. J. Epidemiol. 168 (4): 374–83; discussion 384–90. DOI:10.1093/aje/kwn156. PMID 18611956. Research Blogging.
- ↑ Gelfand, Alan E.; Sudipto Banerjee; Carlin, Bradley P. (2003). Hierarchical Modeling and Analysis for Spatial Data (Monographs on Statistics and Applied Probability). Boca Raton: Chapman & Hall/CRC. LCC QA278.2 .B36. ISBN 1-58488-410-X.
- ↑ Luce BR, Kramer JM, Goodman SN, et al. (June 2009). "Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change". Ann. Intern. Med. 151 (3). PMID 19567619. [e]
- ↑ Anonymous. Health Care: Technology Assessment Subdirectory Page (English). Agency for Healthcare Research and Quality. Retrieved on 2009-08-03.
- ↑ Jeffreys, Harold [1961] (1998). Theory of probability. Oxford: Clarendon Press. ISBN 0-19-850368-7.